T1	p 18 135	patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin
T2	p 401 447	patients with metastatic breast cancer ( MBC )
T3	p 636 655	n = 509 ) ( O'Brien
T4	i 124 172	doxorubicin or pegylated liposomal doxorubicin :
T5	i 314 326	chemotherapy
T6	i 332 351	doxorubicin ( DOX )
T7	i 357 396	pegylated liposomal formulation ( PLD )
T8	i 524 532	DOX ( 60
T9	i 550 582	3 weeks ) or PLD ( 50 mg/m ( 2 )
T10	i 589 590	4
T11	i 597 598	)
T12	i 613 625	line therapy
T13	i 648 655	O'Brien
T14	i 1378 1390	chemotherapy
T15	i 1393 1396	DOX
T16	i 1404 1407	PLD
T17	i 1813 1859	granulocyte colony stimulating factor or PLD )
T18	o 729 739	neutrophil
T19	o 831 842	neutropenia
T20	o 1280 1305	absolute neutrophil count
T21	o 1527 1536	threshold